Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11610052 | 0.90 | GABRA1 (0.41) | GABRA1GABRB2TAAR1HTR1ADRD2 | |
| SCHEMBL8625068 | 0.79 | TAAR1 (0.43) | GABRA1GABRB2TAAR1HTR1ADRD2 | |
| SCHEMBL8626163 | 0.79 | TAAR1 (0.36) | GABRA1GABRB2TAAR1HTR1ADRD2 | |
| SCHEMBL9616491 | 0.78 | NOS3 (0.31) | — | |
| SCHEMBL10883141 | 0.78 | PTPN1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL10879822 | 0.77 | NOS3 (0.30) | — | |
| Clonidine SCHEMBL18050244 | 0.77 | MAPT (0.34) | TAAR1HTR1AHTR2CALDH1A1 | |
| Hydrochloric Acid SCHEMBL10814689 | 0.75 | — | — | |
| SCHEMBL8622574 | 0.74 | GRIA1 (0.34) | HTR2CALDH1A1LMNA | |
| SCHEMBL14547336 | 0.74 | PNMT (0.32) | TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
| EP-0326936-A2 | Use of 2-(phenyl-amino)-2-imidazolines in the application of shock therapy | BOEHRINGER INGELHEIM KG (DE) | 1989-08-09 | — | — | EP | disclosed |
| US-4678775-A | P-OCTOPAMINE AGONIST, STIMULATOR OF ADENYLATE CYCLASE, ANALOG OF CYCLIC ADENOSINE MONOPHOSPHATE | GENERAL HOSPITAL CORPORATION THE | 1987-07-07 | — | — | US | disclosed |
| EP-0081923-B1 | 2-(TRISUBSTITUTED PHENYLIMINO)-IMIDAZOLINES | ALCON LABORATORIES, INC. (US) | 1987-01-21 | — | — | EP | disclosed |
| EP-0179881-A1 | PEST CONTROLLING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-05-07 | — | — | EP | disclosed |
| EP-0081924-B1 | TOPICAL COMPOSTIONS FOR LOWERING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1986-02-19 | — | — | EP | disclosed |
| WO-1985005038-A1 | PEST CONTROLLING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1985-11-21 | — | — | WO | disclosed |
| US-4517199-A | TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4515800-A | GLAUCOMA | ALCON MANUFACTURING, LTD. | 1985-05-07 | — | — | US | disclosed |
| US-4461904-A | 2-(Trisubstituted phenylimino)-imidazolines | ALCON LABORATORIES, INC. (US) | 1984-07-24 | — | — | US | disclosed |
| EP-0081924-A1 | Topical compostions for lowering intraocular pressure | ALCON LABORATORIES, INC. (US) | 1983-06-22 | — | — | EP | disclosed |
| EP-0081923-A2 | 2-(Trisubstituted phenylimino)-imidazolines | ALCON LABORATORIES, INC. (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | GABRA1 505/4885GABRB2 336/4885TAAR1 232/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | GABRA1 2016/4885GABRB2 761/4885TAAR1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.